HUTCHMED Reports Strong Phase II Fanregratinib Data in ICC
HONG KONG, SHANGHAI & FLORHAM PARK, N.J., June 25, 2026 HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) announced that pivotal Phase II registration...
HUTCHMED
Advertisement
HUTCHMED Reports Positive Phase III Sovleplenib Results in wAIHA
Hong Kong, Shanghai & Florham Park, N.J., June 12, 2026 HUTCHMED (China) Limited announced positive results from the Phase...
HUTCHMED Advances Sovleplenib NDA for wAIHA in China
HONG KONG, SHANGHAI & FLORHAM PARK, N.J., April 29, 2026 HUTCHMED (China) Limited has announced that the New Drug...
HUTCHMED’s Savolitinib NDA Gains Priority Review in China
Hong Kong / Shanghai | December 30, 2025 — HUTCHMED announced that China’s drug regulator has accepted the New...
Advertisement
